Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.39 |
| ▸ | NOS3 | P29474 | 2/20 | 0.37 |
| ▸ | NOS1 | P29475 | 2/20 | 0.37 |
| ▸ | NOS2 | P35228 | 2/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2545752 | 0.86 | GABRA1 (0.40) | GABRA1GABRB2NOS3NOS1NOS2 | |
| SCHEMBL29173184 | 0.79 | GABRA1 (0.41) | GABRA1GABRB2NOS3NOS1NOS2 | |
| SCHEMBL11803496 | 0.78 | GABRA1 (0.40) | GABRA1GABRB2NOS3NOS1NOS2 | |
| SCHEMBL20467009 | 0.78 | CYP3A4 (0.41) | TSHRLMNACYP3A4SLC6A2TAAR1 | |
| SCHEMBL6881722 | 0.76 | TSHR (0.44) | GABRA1GABRB2POLBTSHRCA1 | |
| SCHEMBL19750124 | 0.76 | MGLL (0.37) | GABRA1GABRB2LMNATAAR1SMN1; SMN2 | |
| SCHEMBL22180258 | 0.76 | TAAR1 (0.36) | TAAR1 | |
| SCHEMBL10473754 | 0.76 | ESR1 (0.44) | TSHRLMNACYP1A2BLML3MBTL1 | |
| SCHEMBL23188464 | 0.74 | — | — | |
| SCHEMBL1228799 | 0.74 | GABRA1 (0.44) | GABRA1GABRB2GABRG2GABRB3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3371190-B1 | HETEROCYCLIC COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORP (US) | 2022-03-30 | — | — | EP | disclosed |
| EP-3458458-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | Aptinyx Inc. (US) | 2019-03-27 | — | — | EP | disclosed |
| EP-3397629-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VPS-3, Inc. (US) | 2018-11-07 | — | — | EP | disclosed |
| US-20180290976-A1 | LSD1 INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. | 2018-10-11 | — | — | US | disclosed |
| EP-3341374-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO NTRK | Blueprint Medicines Corporation (US) | 2018-07-04 | — | — | EP | disclosed |
| EP-3283473-A1 | GHRELIN O-ACYL TRANSFERASE INHIBITORS | Eli Lilly and Company (US) | 2018-02-21 | — | — | EP | disclosed |
| WO-2017201283-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017117393-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2017-07-06 | — | — | WO | disclosed |
| WO-2017035354-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO NTRK | BLUEPRINT MEDICINES CORPORATION (US) | 2017-03-02 | — | — | WO | disclosed |
| WO-2016168222-A1 | GHRELIN O-ACYL TRANSFERASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2016-10-20 | — | — | WO | disclosed |
| WO-2006091697-A1 | DOPAMINE TRANSPORTER INHIBITORS FOR USE IN TREATMENT OF MOVEMENT DISORDERS AND OTHER CNS INDICATIONS | PSYCHENOMICS, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
| WO-2005016884-A9 | CYCLOPROPYL DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | LUNDBECK & CO AS H (DK) | 2006-03-16 | — | — | WO | disclosed |
| US-20060009497-A1 | Novel tetrahydropyridine derivatives as renin inhibitors | ACTELION PHARMACEUTICALS, LTD. (CH) | 2006-01-12 | — | — | US | disclosed |
| WO-2005097199-A1 | TRIPARTITE CONJUGATES CONTAINING A STRUCTURE INTERACTING WITH CELL MEMBRANE RAFTS AND THEIR USE | JADOLABS GMBH (DE) | 2005-10-20 | — | — | WO | disclosed |
| US-20050113563-A1 | Chemical peptide ligation with three or more components | ASTRAZENECA PHARMACEUTICALS LP | 2005-05-26 | — | — | US | disclosed |
| US-6825350-B2 | ADMINISTERING DOSAGE OF IMMUNOLOGY RESPONSE MODERATOR | 3M INNOVATIVE PROPERTIES COMPANY | 2004-11-30 | — | — | US | disclosed |
| US-20030027850-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | ASHWELL SUSAN (US) | 2003-02-06 | — | — | US | disclosed |
| US-6353099-B1 | USED FOR PREVENTION OR TREATMENT OF DISEASES, DISORDERS, CONDITIONS OR SYMPTOMS MEDIATED BY CELL ADHESION IN MAMMAL | MERCK & CO., INC. | 2002-03-05 | — | — | US | disclosed |
| US-6271225-B1 | PSYCHOLOGICAL DISORDERS | WELFIDE CORPORATION (JP) | 2001-08-07 | — | — | US | disclosed |
| CN-1113236-A | Non-peptidyl tachykinin receptor antagonists | LILLY CO ELI (US) | 1995-12-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113563-A1 | Chemical peptide ligation with three or more components | VIP, IAPP, DNPEP | GABRA1 2486/4885GABRB2 2217/4885NOS3 1247/4885 |
| US-20030027850-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, L1CAM | GABRA1 989/4885GABRB2 494/4885NOS3 1336/4885 |
| US-20180290976-A1 | LSD1 INHIBITORS AND USES THEREOF | KDM1B, KDM1A, KDM2A | GABRA1 2467/4885GABRB2 1592/4885NOS3 688/4885 |
| US-20060009497-A1 | Novel tetrahydropyridine derivatives as renin inhibitors | REN, ACE, ACE2 | GABRA1 2674/4885GABRB2 2362/4885NOS3 2108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.